JP2023120388A - external composition - Google Patents
external composition Download PDFInfo
- Publication number
- JP2023120388A JP2023120388A JP2023103320A JP2023103320A JP2023120388A JP 2023120388 A JP2023120388 A JP 2023120388A JP 2023103320 A JP2023103320 A JP 2023103320A JP 2023103320 A JP2023103320 A JP 2023103320A JP 2023120388 A JP2023120388 A JP 2023120388A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- external use
- phosphocholine group
- containing polymer
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 83
- 125000002525 phosphocholine group Chemical group OP(=O)(OCC[N+](C)(C)C)O* 0.000 claims abstract description 50
- 229920000642 polymer Polymers 0.000 claims abstract description 36
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims abstract description 30
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims abstract description 24
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims abstract description 24
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims abstract description 23
- 238000000034 method Methods 0.000 claims abstract description 8
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical class OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229920001577 copolymer Polymers 0.000 claims description 18
- ZSZRUEAFVQITHH-UHFFFAOYSA-N 2-(2-methylprop-2-enoyloxy)ethyl 2-(trimethylazaniumyl)ethyl phosphate Chemical group CC(=C)C(=O)OCCOP([O-])(=O)OCC[N+](C)(C)C ZSZRUEAFVQITHH-UHFFFAOYSA-N 0.000 claims description 15
- 239000013049 sediment Substances 0.000 claims description 14
- SOGAXMICEFXMKE-UHFFFAOYSA-N alpha-Methyl-n-butyl acrylate Natural products CCCCOC(=O)C(C)=C SOGAXMICEFXMKE-UHFFFAOYSA-N 0.000 claims description 12
- 150000005846 sugar alcohols Polymers 0.000 claims description 9
- 229920001499 Heparinoid Polymers 0.000 claims description 6
- 239000002554 heparinoid Substances 0.000 claims description 6
- 239000002244 precipitate Substances 0.000 abstract description 17
- 238000002360 preparation method Methods 0.000 abstract description 11
- 238000003860 storage Methods 0.000 abstract description 9
- 239000002628 heparin derivative Substances 0.000 abstract description 5
- 239000000463 material Substances 0.000 abstract description 3
- 239000000178 monomer Substances 0.000 description 23
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 18
- -1 polyoxyethylene Polymers 0.000 description 18
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 17
- 239000007787 solid Substances 0.000 description 15
- 210000003491 skin Anatomy 0.000 description 12
- 239000002202 Polyethylene glycol Substances 0.000 description 11
- 229920001223 polyethylene glycol Polymers 0.000 description 11
- 238000009472 formulation Methods 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 8
- 239000000499 gel Substances 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 239000006210 lotion Substances 0.000 description 7
- 230000003020 moisturizing effect Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 125000000217 alkyl group Chemical group 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 229920001451 polypropylene glycol Polymers 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 229920003091 Methocel™ Polymers 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229920002683 Glycosaminoglycan Polymers 0.000 description 3
- 239000004166 Lanolin Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 3
- 229920001519 homopolymer Polymers 0.000 description 3
- 235000019388 lanolin Nutrition 0.000 description 3
- 229940039717 lanolin Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229920001296 polysiloxane Polymers 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 210000000434 stratum corneum Anatomy 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- UYZQWKKNVBJVOF-UHFFFAOYSA-N 1-decoxytetradecane Chemical compound CCCCCCCCCCCCCCOCCCCCCCCCC UYZQWKKNVBJVOF-UHFFFAOYSA-N 0.000 description 2
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- ASKIVFGGGGIGKH-UHFFFAOYSA-N 2,3-dihydroxypropyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCC(O)CO ASKIVFGGGGIGKH-UHFFFAOYSA-N 0.000 description 2
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N Alanine Chemical compound CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 2
- 241000723346 Cinnamomum camphora Species 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 229920003102 Methocel™ E4M Polymers 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- KVYGGMBOZFWZBQ-UHFFFAOYSA-N benzyl nicotinate Chemical compound C=1C=CN=CC=1C(=O)OCC1=CC=CC=C1 KVYGGMBOZFWZBQ-UHFFFAOYSA-N 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 229930008380 camphor Natural products 0.000 description 2
- 229960000846 camphor Drugs 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 229940074979 cetyl palmitate Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- NEHNMFOYXAPHSD-UHFFFAOYSA-N citronellal Chemical compound O=CCC(C)CCC=C(C)C NEHNMFOYXAPHSD-UHFFFAOYSA-N 0.000 description 2
- 239000002826 coolant Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 229940075507 glyceryl monostearate Drugs 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 2
- 229940075495 isopropyl palmitate Drugs 0.000 description 2
- 229940041616 menthol Drugs 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- RGOVYLWUIBMPGK-UHFFFAOYSA-N nonivamide Chemical compound CCCCCCCCC(=O)NCC1=CC=C(O)C(OC)=C1 RGOVYLWUIBMPGK-UHFFFAOYSA-N 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 1
- CRDAMVZIKSXKFV-FBXUGWQNSA-N (2-cis,6-cis)-farnesol Chemical compound CC(C)=CCC\C(C)=C/CC\C(C)=C/CO CRDAMVZIKSXKFV-FBXUGWQNSA-N 0.000 description 1
- 239000000260 (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol Substances 0.000 description 1
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 1
- HOVAGTYPODGVJG-UVSYOFPXSA-N (3s,5r)-2-(hydroxymethyl)-6-methoxyoxane-3,4,5-triol Chemical compound COC1OC(CO)[C@@H](O)C(O)[C@H]1O HOVAGTYPODGVJG-UVSYOFPXSA-N 0.000 description 1
- QYIXCDOBOSTCEI-QCYZZNICSA-N (5alpha)-cholestan-3beta-ol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-QCYZZNICSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- JPPRXACMNPYJNK-UHFFFAOYSA-N 1-docosoxydocosane Chemical compound CCCCCCCCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCCCCCCCC JPPRXACMNPYJNK-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- JWKSQNWLEIABLH-UHFFFAOYSA-N 1-octan-2-yloxydodecane Chemical compound CCCCCCCCCCCCOC(C)CCCCCC JWKSQNWLEIABLH-UHFFFAOYSA-N 0.000 description 1
- LVOGXJMCDAOKSQ-UHFFFAOYSA-N 10-oxo-10-propan-2-yloxydecanoic acid Chemical compound CC(C)OC(=O)CCCCCCCCC(O)=O LVOGXJMCDAOKSQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 description 1
- ZVUNTIMPQCQCAQ-UHFFFAOYSA-N 2-dodecanoyloxyethyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCC ZVUNTIMPQCQCAQ-UHFFFAOYSA-N 0.000 description 1
- IKVCSHRLYCDSFD-UHFFFAOYSA-N 2-hexadecanoyloxyethyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCCCCCC IKVCSHRLYCDSFD-UHFFFAOYSA-N 0.000 description 1
- BXCRLBBIZJSWNS-UHFFFAOYSA-N 2-hydroxyethyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCCO BXCRLBBIZJSWNS-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- XPFCZYUVICHKDS-UHFFFAOYSA-N 3-methylbutane-1,3-diol Chemical compound CC(C)(O)CCO XPFCZYUVICHKDS-UHFFFAOYSA-N 0.000 description 1
- MOMKYJPSVWEWPM-UHFFFAOYSA-N 4-(chloromethyl)-2-(4-methylphenyl)-1,3-thiazole Chemical compound C1=CC(C)=CC=C1C1=NC(CCl)=CS1 MOMKYJPSVWEWPM-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- QSAZFJIPYFLRJS-UHFFFAOYSA-N C(C(=C)C)(=O)OCCP(=O)=C(O)CN Chemical compound C(C(=C)C)(=O)OCCP(=O)=C(O)CN QSAZFJIPYFLRJS-UHFFFAOYSA-N 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- ZDQWESQEGGJUCH-UHFFFAOYSA-N Diisopropyl adipate Chemical compound CC(C)OC(=O)CCCCC(=O)OC(C)C ZDQWESQEGGJUCH-UHFFFAOYSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- FPVVYTCTZKCSOJ-UHFFFAOYSA-N Ethylene glycol distearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCCCCCCCC FPVVYTCTZKCSOJ-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- QQILFGKZUJYXGS-UHFFFAOYSA-N Indigo dye Chemical compound C1=CC=C2C(=O)C(C3=C(C4=CC=CC=C4N3)O)=NC2=C1 QQILFGKZUJYXGS-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- VNQABZCSYCTZMS-UHFFFAOYSA-N Orthoform Chemical compound COC(=O)C1=CC=C(O)C(N)=C1 VNQABZCSYCTZMS-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- KCLANYCVBBTKTO-UHFFFAOYSA-N Proparacaine Chemical compound CCCOC1=CC=C(C(=O)OCCN(CC)CC)C=C1N KCLANYCVBBTKTO-UHFFFAOYSA-N 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- SLINHMUFWFWBMU-UHFFFAOYSA-N Triisopropanolamine Chemical compound CC(O)CN(CC(C)O)CC(C)O SLINHMUFWFWBMU-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- NCHJGQKLPRTMAO-XWVZOOPGSA-N [(2R)-2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NCHJGQKLPRTMAO-XWVZOOPGSA-N 0.000 description 1
- RUYKUXOULSOEPZ-UHFFFAOYSA-N [2-hydroxy-3-(2-methylprop-2-enoyloxy)propyl]-trimethylazanium Chemical compound CC(=C)C(=O)OCC(O)C[N+](C)(C)C RUYKUXOULSOEPZ-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- QYIXCDOBOSTCEI-UHFFFAOYSA-N alpha-cholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 QYIXCDOBOSTCEI-UHFFFAOYSA-N 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 229950004580 benzyl nicotinate Drugs 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- QRZAKQDHEVVFRX-UHFFFAOYSA-N biphenyl-4-ylacetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1C1=CC=CC=C1 QRZAKQDHEVVFRX-UHFFFAOYSA-N 0.000 description 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 1
- 229940116229 borneol Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 239000004204 candelilla wax Substances 0.000 description 1
- 235000013868 candelilla wax Nutrition 0.000 description 1
- 229940073532 candelilla wax Drugs 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 229940043350 citral Drugs 0.000 description 1
- 229930003633 citronellal Natural products 0.000 description 1
- 235000000983 citronellal Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 229960001193 diclofenac sodium Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 1
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229950010030 dl-alanine Drugs 0.000 description 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 239000010696 ester oil Substances 0.000 description 1
- RMVRNAXXHCXCLR-UHFFFAOYSA-N ethenyl 2-methylprop-2-enoate;2-hydroxyethyl-dimethyl-[(oxo-$l^{5}-phosphanylidyne)methyl]azanium Chemical compound CC(=C)C(=O)OC=C.OCC[N+](C)(C)C#P=O RMVRNAXXHCXCLR-UHFFFAOYSA-N 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- FMMOOAYVCKXGMF-MURFETPASA-N ethyl linoleate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OCC FMMOOAYVCKXGMF-MURFETPASA-N 0.000 description 1
- 229940031016 ethyl linoleate Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 229940043259 farnesol Drugs 0.000 description 1
- 229930002886 farnesol Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229960000192 felbinac Drugs 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- WTEVQBCEXWBHNA-JXMROGBWSA-N geranial Chemical compound CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 229940100608 glycol distearate Drugs 0.000 description 1
- IUJAMGNYPWYUPM-UHFFFAOYSA-N hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- XJNUECKWDBNFJV-UHFFFAOYSA-N hexadecyl 2-ethylhexanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)C(CC)CCCC XJNUECKWDBNFJV-UHFFFAOYSA-N 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- FMMOOAYVCKXGMF-UHFFFAOYSA-N linoleic acid ethyl ester Natural products CCCCCC=CCC=CCCCCCCCC(=O)OCC FMMOOAYVCKXGMF-UHFFFAOYSA-N 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 229960002373 loxoprofen Drugs 0.000 description 1
- WORCCYVLMMTGFR-UHFFFAOYSA-M loxoprofen sodium Chemical compound [Na+].C1=CC(C(C([O-])=O)C)=CC=C1CC1C(=O)CCC1 WORCCYVLMMTGFR-UHFFFAOYSA-M 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- HOVAGTYPODGVJG-UHFFFAOYSA-N methyl beta-galactoside Natural products COC1OC(CO)C(O)C(O)C1O HOVAGTYPODGVJG-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229940043348 myristyl alcohol Drugs 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- CTIQLGJVGNGFEW-UHFFFAOYSA-L naphthol yellow S Chemical compound [Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C([O-])=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 CTIQLGJVGNGFEW-UHFFFAOYSA-L 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- KSCKTBJJRVPGKM-UHFFFAOYSA-N octan-1-olate;titanium(4+) Chemical compound [Ti+4].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-] KSCKTBJJRVPGKM-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 229950006098 orthocaine Drugs 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 229940098695 palmitic acid Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229950004354 phosphorylcholine Drugs 0.000 description 1
- PYJNAPOPMIJKJZ-UHFFFAOYSA-N phosphorylcholine chloride Chemical compound [Cl-].C[N+](C)(C)CCOP(O)(O)=O PYJNAPOPMIJKJZ-UHFFFAOYSA-N 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- CHWRSCGUEQEHOH-UHFFFAOYSA-N potassium oxide Chemical compound [O-2].[K+].[K+] CHWRSCGUEQEHOH-UHFFFAOYSA-N 0.000 description 1
- 229910001950 potassium oxide Inorganic materials 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 229960003981 proparacaine Drugs 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 229940077082 red pepper extract Drugs 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229940092258 rosemary extract Drugs 0.000 description 1
- 235000020748 rosemary extract Nutrition 0.000 description 1
- 239000001233 rosmarinus officinalis l. extract Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000003009 skin protective agent Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- 239000004320 sodium erythorbate Substances 0.000 description 1
- 235000010352 sodium erythorbate Nutrition 0.000 description 1
- 235000019983 sodium metaphosphate Nutrition 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- RBWSWDPRDBEWCR-RKJRWTFHSA-N sodium;(2r)-2-[(2r)-3,4-dihydroxy-5-oxo-2h-furan-2-yl]-2-hydroxyethanolate Chemical compound [Na+].[O-]C[C@@H](O)[C@H]1OC(=O)C(O)=C1O RBWSWDPRDBEWCR-RKJRWTFHSA-N 0.000 description 1
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
- SONHXMAHPHADTF-UHFFFAOYSA-M sodium;2-methylprop-2-enoate Chemical compound [Na+].CC(=C)C([O-])=O SONHXMAHPHADTF-UHFFFAOYSA-M 0.000 description 1
- CRPCXAMJWCDHFM-UHFFFAOYSA-M sodium;5-oxopyrrolidine-2-carboxylate Chemical compound [Na+].[O-]C(=O)C1CCC(=O)N1 CRPCXAMJWCDHFM-UHFFFAOYSA-M 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940044609 sulfur dioxide Drugs 0.000 description 1
- 235000010269 sulphur dioxide Nutrition 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960002372 tetracaine Drugs 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- CRDAMVZIKSXKFV-UHFFFAOYSA-N trans-Farnesol Natural products CC(C)=CCCC(C)=CCCC(C)=CCO CRDAMVZIKSXKFV-UHFFFAOYSA-N 0.000 description 1
- HVUCRESARJLKJG-UHFFFAOYSA-K trisodium 1-hexadecoxyhexadecane phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O.CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC HVUCRESARJLKJG-UHFFFAOYSA-K 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Abstract
Description
本発明は、ホスホコリン基含有重合体、及びヒドロキシプロピルメチルセルロースを含んでいながらも、浮遊物や沈殿物の発生を抑制でき、優れた外観性状を有する外用組成物に関する。 TECHNICAL FIELD The present invention relates to a composition for external use that contains a phosphocholine group-containing polymer and hydroxypropylmethyl cellulose, yet is capable of suppressing the generation of floating matter and sediment, and has excellent appearance properties.
従来、2-メタクリロイルオキシエチルホスホリルコリン・メタクリル酸ブチル共重合体等のホスホコリン基含有重合体は、角質層に浸透して、水分の蒸発を防ぎ、肌のバリア機能をサポートし、様々な刺激物質からから肌を保護する作用があることが知られており、外用組成物の配合成分として注目を浴びている。そこで、ホスホコリン基含有重合体を配合した外用組成物の処方についても、種々検討されている。例えば、特許文献1には、特定の平均分子量で特定の構造のホスホコリン基含有重合体と、特定の平均分子量のポリエチレングリコール及び/又はポリオキシエチレンメチルグルコシドとを含むスキンケア
組成物は、皮膚への塗布時の滑り性に優れ、且つ使用感が良好であることが報告されている。
Conventionally, phosphocholine group-containing polymers such as 2-methacryloyloxyethylphosphorylcholine and butyl methacrylate copolymer penetrate the stratum corneum, prevent evaporation of moisture, support the skin barrier function, and protect against various stimuli. It is known to have the effect of protecting the skin from toxins, and is attracting attention as a compounding ingredient of external compositions. Therefore, various studies have been made on the formulation of an external composition containing a phosphocholine group-containing polymer. For example, in Patent Document 1, a skin care composition containing a phosphocholine group-containing polymer having a specific average molecular weight and a specific structure, and polyethylene glycol and/or polyoxyethylene methyl glucoside having a specific average molecular weight is applied to the skin. It has been reported that it has excellent slipperiness when applied and has a good feeling in use.
また、外用組成物にヒドロキシプロピルメチルセルロースを配合すると、粘性、皮膚での滞留性等の特性が向上することが知られている。 In addition, it is known that when hydroxypropylmethylcellulose is blended into a composition for external use, properties such as viscosity and retention on the skin are improved.
近年、外用組成物の使用感や機能性に対する要求性能は高まる一方であり、ホスホコリン基含有重合体の作用とヒドロキシプロピルメチルセルロースの作用を併せ持つ外用組成物を提供できれば、消費者のスキンケアに対する満足度を高めることが期待される。 In recent years, the demand for the feel of use and functionality of topical compositions has been increasing, and if we can provide topical compositions that combine the action of a phosphocholine group-containing polymer and the action of hydroxypropylmethyl cellulose, we will increase consumer satisfaction with skin care. expected to increase.
一方、外用組成物を実用化するには、機能性のみならず、優れた外観性状を備えさせることについても十分に配慮する必要があるが、従来技術では、ホスホコリン基含有重合体及びヒドロキシプロピルメチルセルロースを含む外用組成物の外観性状については十分な検討がなされていないのが現状である。 On the other hand, in order to put a composition for external use into practical use, it is necessary to give sufficient consideration not only to its functionality but also to its excellent appearance. At present, the external appearance properties of compositions for external use containing are not sufficiently studied.
本発明者は、ホスホコリン基含有重合体及びヒドロキシプロピルメチルセルロースを含む外用組成物を実用化すべく検討を進めたところ、ホスホコリン基含有重合体及びヒドロキシプロピルメチルセルロースを含む外用組成物では、析出物が生じて、浮遊物による白濁や沈殿物の生成が起こり、実用化に耐え得る外観性状を備えることができないという新たな課題に直面した。 The inventors of the present invention conducted studies to put a composition for external use containing a phosphocholine group-containing polymer and hydroxypropylmethylcellulose into practical use. In addition, we faced a new problem that cloudiness and precipitation due to floating matter occurred, and it was not possible to provide appearance properties that could withstand practical use.
そこで、本発明の目的は、ホスホコリン基含有重合体及びヒドロキシプロピルメチルセルロースを含む外用組成物において、浮遊物や沈殿物の発生を抑制でき、優れた外観性状を備えさせる製剤技術を提供することである。 Accordingly, an object of the present invention is to provide a formulation technology capable of suppressing the generation of suspended solids and precipitates and providing excellent appearance properties in an external composition containing a phosphocholine group-containing polymer and hydroxypropylmethylcellulose. .
本発明者は、前記課題を解決すべく鋭意検討を行ったところ、ホスホコリン基含有重合体及びヒドロキシプロピルメチルセルロースと共に、ヘパリン類似物質を含有させた外用組成物は、保存しても浮遊物や沈殿物の発生を抑制でき、優れた外観性状を備え得ることを見出した。 The present inventors conducted intensive studies to solve the above-mentioned problems, and found that an external composition containing a heparin-like substance together with a phosphocholine group-containing polymer and hydroxypropylmethyl cellulose produced suspended solids and sediments even after storage. It was found that the occurrence of can be suppressed and excellent appearance properties can be provided.
即ち、本発明は、下記に掲げる態様の発明を提供する。
項1. (A)ホスホコリン基含有重合体、(B)ヒドロキシプロピルメチルセルロース、及び(C)ヘパリン類似物質を含有する、外用組成物。
項2. 前記(A)ホスホコリン基含有重合体が、2-メタクリロイルオキシエチルホスホリルコリン・メタクリル酸ブチル共重合体である、項1に記載の外用組成物。
項3. 前記(C)ヘパリン類似物質を0.01~5重量%含有する、項1又は2に記載の外用組成物。
項4. 更に、(D)多価アルコールを含有する、項1~3のいずれかに記載の外用組成物。
項5. ホスホコリン基含有重合体、及びヒドロキシプロピルメチルセルロースを含む外用組成物において、浮遊物及び/又は沈殿物の発生を抑制する方法であって、
外用組成物に、(A)ホスホコリン基含有重合体、及び(B)ヒドロキシプロピルメチルセルロースと共に、(C)ヘパリン類似物質を配合する、
前記外用組成物の浮遊物及び/又は沈殿物の発生抑制方法。
That is, the present invention provides inventions in the following aspects.
Section 1. A composition for external use comprising (A) a phosphocholine group-containing polymer, (B) hydroxypropylmethylcellulose, and (C) a heparinoid.
Section 2. Item 2. The composition for external use according to Item 1, wherein the (A) phosphocholine group-containing polymer is a 2-methacryloyloxyethylphosphorylcholine/butyl methacrylate copolymer.
Item 3. Item 3. The composition for external use according to Item 1 or 2, containing 0.01 to 5% by weight of (C) the heparinoid.
Section 4. Item 4. The composition for external use according to any one of Items 1 to 3, further comprising (D) a polyhydric alcohol.
Item 5. A method for suppressing the generation of floating matter and/or sediment in an external composition containing a phosphocholine group-containing polymer and hydroxypropylmethylcellulose,
(A) a phosphocholine group-containing polymer and (B) hydroxypropylmethylcellulose, and (C) a heparin analogue are blended into the composition for external use;
A method for suppressing the generation of floating matter and/or sediments of the composition for external use.
本発明の外用組成物は、ホスホコリン基含有重合体及びヒドロキシプロピルメチルセルロースを含んでいながらも、浮遊物や沈殿物の発生を抑制でき、優れた外観性状を備えさせることができる。 The composition for external use of the present invention can suppress the generation of floating matter and sediment, and can have excellent appearance properties, even though it contains a phosphocholine group-containing polymer and hydroxypropylmethylcellulose.
1.外用組成物
本発明の外用組成物は、ホスホコリン基含有重合体((A)成分と表記することもある)、ヒドロキシプロピルメチルセルロース((B)成分と表記することもある)、及びヘパリン類似物質((C)成分と表記することもある)を含有することを特徴とする。以下、本発明の外用組成物について詳述する。
1. Composition for external use The composition for external use of the present invention comprises a phosphocholine group-containing polymer (sometimes referred to as component (A)), hydroxypropylmethylcellulose (sometimes referred to as component (B)), and a heparin analogue ( (C) It is characterized by containing component. The composition for external use of the present invention is described in detail below.
(A)ホスホコリン基含有重合体
ホスホコリン基含有重合体とは、ホスホコリン基を含む単量体(以下、「ホスホコリン基含有単量体」と表記することがある)が重合したポリマーであり、保湿作用、角質層のバリア機能等を有する公知の成分である。
(A) Phosphocholine group-containing polymer A phosphocholine group-containing polymer is a polymer obtained by polymerizing a monomer containing a phosphocholine group (hereinafter sometimes referred to as "phosphocholine group-containing monomer"), and has a moisturizing effect. , is a known component having a barrier function for the stratum corneum.
本発明で使用されるホスホコリン基含有重合体において、ホスホコリン基含有単量体の種類については、特に制限されないが、例えば、ホスホコリン基とビニル基を有する単量体が挙げられる。ホスホコリン基含有単量体として、より具体的には、2-メタクリロイルオキシエチルホスホリルコリン、2-メタクリロイルオキシエチルホスホリルエタノールアミン等が挙げられる。ホスホコリン基含有重合体において、ホスホコリン基含有単量体は1種単独で含まれていてもよく、また2種以上組み合わされて含まれていてもよい。これらのホスホコリン基含有単量体の中でも、浮遊物や沈殿物の発生をより一層効果的に抑制するという観点から、好ましくは2-メタクリロイルオキシエチルホスホリルコリンが挙げられる。 In the phosphocholine group-containing polymer used in the present invention, the type of the phosphocholine group-containing monomer is not particularly limited, but examples thereof include monomers having a phosphocholine group and a vinyl group. More specific examples of the phosphocholine group-containing monomer include 2-methacryloyloxyethylphosphorylcholine, 2-methacryloyloxyethylphosphorylethanolamine, and the like. In the phosphocholine group-containing polymer, the phosphocholine group-containing monomer may be contained singly or in combination of two or more. Among these phosphocholine group-containing monomers, 2-methacryloyloxyethylphosphorylcholine is preferred from the viewpoint of more effectively suppressing the generation of suspended solids and precipitates.
本発明で使用されるホスホコリン基含有重合体は、1種のホスホコリン基含有単量体からなる単重合体であってもよく、また2種以上の単量体からなる共重合体であってもよい。 The phosphocholine group-containing polymer used in the present invention may be a homopolymer consisting of one type of phosphocholine group-containing monomer, or a copolymer consisting of two or more types of monomers. good.
ホスホコリン基含有重合体が共重合体である場合、2種以上のホスホコリン基含有単量体からなる共重合体であってもよく、また少なくとも1種のホスホコリン基含有単量体と少なくとも1種のホスホコリン基含有単量体以外の単量体からなる共重合体であってもよい。 When the phosphocholine group-containing polymer is a copolymer, it may be a copolymer composed of two or more phosphocholine group-containing monomers, or at least one phosphocholine group-containing monomer and at least one A copolymer composed of a monomer other than the phosphocholine group-containing monomer may also be used.
ホスホコリン基含有重合体に含まれるホスホコリン基含有単量体以外の単量体の種類については、薬学的に許容されるものであってホスホコリン基含有単量とラジカル重合可能であることを限度として特に制限されないが、例えば、ビニル基を有する単量体が挙げられる。ホスホコリン基含有単量体以外の単量体として、具体的には、メチル(メタ)アクリレート、エチル(メタ)アクリレート、ブチル(メタ)アクリレート、ラウリル(メタ)アクリレート、ステアリル(メタ)アクリレート、2-エチルヘキシル(メタ)アクリレート等のアルキル(メタ)アクリレート;ベンジル(メタ)アクリレート、フェノキシエチル(メタ)アクリレート、シクロヘキシル(メタ)アクリレート、ポリプロピレングリコールモノ(メタ)アクリレート、ポリテトラメチレングリコールモノ(メタ)アクリレート、ポリプロピレングリコールジ(メタ)アクリレート、ポリテトラメチレングリコールモノ(メタ)アクリレート、ポリプロピレングリコールポリエチレングリコールモノ(メタ)アクリレート、メタクリル酸ナトリウム、2-ヒドロキシ-3-メタクリロイルオキシプロピルトリメチルアンモニウム等が挙げられる。ホスホコリン基含有重合体において、ホスホコリン基含有単量体以外の単量体は1種単独で含まれていてもよく、また2種以上組み合わされて含まれていてもよい。これらのホスホコリン基含有単量体以外の単量体の中でも、浮遊物や沈殿物の発生をより一層効果的に抑制するという観点から、好ましくはアルキル(メタ)アクリレート、2-ヒドロキシ-3-メタクリロイルオキシプロピルトリメチルアンモニウム、更に好ましくはアルキル基の炭素数が1~18のアルキル(メタ)アクリレート、より好ましくはアルキル基の炭素数が3~5のアルキル(メタ)アクリレート、特に好ましくはブチル(メタ)アクリレートが挙げられる。なお、本明細書において、「(メタ)アクリレート」とは、メタクリレート及び/又はアクリレートを示す。 Regarding the type of monomer other than the phosphocholine group-containing monomer contained in the phosphocholine group-containing polymer, it is particularly limited to being pharmaceutically acceptable and capable of being radically polymerized with the phosphocholine group-containing monomer. Examples include, but are not limited to, monomers having a vinyl group. Specific examples of monomers other than the phosphocholine group-containing monomer include methyl (meth) acrylate, ethyl (meth) acrylate, butyl (meth) acrylate, lauryl (meth) acrylate, stearyl (meth) acrylate, 2- Alkyl (meth)acrylates such as ethylhexyl (meth)acrylate; benzyl (meth)acrylate, phenoxyethyl (meth)acrylate, cyclohexyl (meth)acrylate, polypropylene glycol mono(meth)acrylate, polytetramethylene glycol mono(meth)acrylate, polypropylene glycol di(meth)acrylate, polytetramethylene glycol mono(meth)acrylate, polypropylene glycol polyethylene glycol mono(meth)acrylate, sodium methacrylate, 2-hydroxy-3-methacryloyloxypropyltrimethylammonium and the like. In the phosphocholine group-containing polymer, monomers other than the phosphocholine group-containing monomer may be contained singly or in combination of two or more. Among the monomers other than these phosphocholine group-containing monomers, alkyl (meth)acrylates and 2-hydroxy-3-methacryloyl are preferred from the viewpoint of more effectively suppressing the generation of suspended solids and precipitates. Oxypropyltrimethylammonium, more preferably alkyl (meth)acrylate having 1 to 18 carbon atoms in the alkyl group, more preferably alkyl (meth)acrylate having 3 to 5 carbon atoms in the alkyl group, particularly preferably butyl (meth) Acrylates are mentioned. In addition, in this specification, "(meth)acrylate" shows a methacrylate and/or an acrylate.
本発明で使用されるホスホコリン基含有重合体として、具体的には、ポリメタクリロイルオキシエチルホスホリルコリン単重合体、2-メタクリロイルオキシエチルホスホリルコリン・メタクリル酸ブチル共重合体(ポリクオタニウム-51)、2-メタクリロイルオキシエチレンホスホリルコリン・メタクリル酸ブチル・メタクリル酸ナトリウム共重合体(ポリクオタニウム-65)、2-メタクリロイルオキシエチルホスホリルコリン・2-ヒドロキシ-3-メタクリロイルオキシプロピルトリメチルアンモニウム共重合体(ポリクオタニウム-64)、2-メタクリロイルオキシエチルホスホリルコリン・メタクリル酸ステアリル共重合体(ポリクオタニウム-61)等が挙げられる。なお、ホスホコリン基含有重合体に関する前記表記において、括弧内の名称は化粧品成分表示名称を示す。 Specific examples of the phosphocholine group-containing polymer used in the present invention include polymethacryloyloxyethylphosphorylcholine homopolymer, 2-methacryloyloxyethylphosphorylcholine/butyl methacrylate copolymer (polyquaternium-51), 2-methacryloyloxy Ethylene Phosphorylcholine/Butyl Methacrylate/Sodium Methacrylate Copolymer (Polyquaternium-65), 2-Methacryloyloxyethyl Phosphorylcholine/2-Hydroxy-3-Methacryloyloxypropyltrimethylammonium Copolymer (Polyquaternium-64), 2-Methacryloyloxy ethylphosphorylcholine/stearyl methacrylate copolymer (polyquaternium-61); Incidentally, in the above notation regarding the phosphocholine group-containing polymer, the name in parentheses indicates the display name of the cosmetic component.
本発明の外用組成物において、ホスホコリン基含有重合体は、1種のものを単独で使用してもよく、また2種以上を組み合わせて使用してもよい。 In the composition for external use of the present invention, the phosphocholine group-containing polymer may be used singly or in combination of two or more.
これらのホスホコリン基含有重合体の中でも、浮遊物や沈殿物の発生をより一層効果的に抑制するという観点から、好ましくは、2-メタクリロイルオキシエチルホスホリルコリン・メタクリル酸ブチル共重合体、ポリメタクリロイルオキシエチルホスホリルコリン単重合体、2-メタクリロイルオキシエチルホスホリルコリン・2-ヒドロキシ-3-メタクリロイルオキシプロピルトリメチルアンモニウム共重合体;更に好ましくは、2-メタクリロイルオキシエチルホスホリルコリン・メタクリル酸ブチル共重合体、2-メタクリロイルオキシエチルホスホリルコリン・2-ヒドロキシ-3-メタクリロイルオキシプロピルトリメチルアンモニウム共重合体;特に好ましくは、2-メタクリロイルオキシエチルホスホリルコリン・メタクリル酸ブチル共重合体が挙げられる。 Among these phosphocholine group-containing polymers, 2-methacryloyloxyethyl phosphorylcholine/butyl methacrylate copolymer and polymethacryloyloxyethyl are preferred from the viewpoint of more effectively suppressing the generation of suspended solids and precipitates. phosphorylcholine homopolymer, 2-methacryloyloxyethyl phosphorylcholine/2-hydroxy-3-methacryloyloxypropyltrimethylammonium copolymer; more preferably 2-methacryloyloxyethyl phosphorylcholine/butyl methacrylate copolymer, 2-methacryloyloxyethyl phosphorylcholine/2-hydroxy-3-methacryloyloxypropyltrimethylammonium copolymer; particularly preferred is 2-methacryloyloxyethylphosphorylcholine/butyl methacrylate copolymer.
本発明の外用組成物において、(A)成分の含有量については、特に制限されず、付与すべき作用等に応じて適宜設定すればよいが、例えば、0.025~1重量%が挙げられる。浮遊物や沈殿物の発生をより一層効果的に抑制するという観点から、(A)成分の含有量として、好ましくは0.05~0.5重量%、更に好ましくは0.1~0.3重量%が挙げられる。 In the composition for external use of the present invention, the content of the component (A) is not particularly limited, and may be appropriately set according to the action to be imparted. . From the viewpoint of more effectively suppressing the generation of suspended solids and sediments, the content of component (A) is preferably 0.05 to 0.5% by weight, more preferably 0.1 to 0.3%. % by weight.
(B)ヒドロキシプロピルメチルセルロース
ヒドロキシプロピルメチルセルロースは、セルロース誘導体であり、ヒプロメロースとも称される化合物である。
(B) Hydroxypropylmethylcellulose Hydroxypropylmethylcellulose is a cellulose derivative and a compound also called hypromellose.
本発明に使用されるヒドロキシプロピルメチルセルロースの置換度タイプについては、特に制限されず、1828、2208、2906、2910のいずれであってもよいが、より一層効果的に相分離を抑制するという観点から、好ましくは2208、2906及び2910の置換度タイプのものが挙げられる。 The substitution degree type of hydroxypropylmethylcellulose used in the present invention is not particularly limited, and may be any of 1828, 2208, 2906, and 2910, from the viewpoint of more effectively suppressing phase separation. , preferably of the 2208, 2906 and 2910 degree of substitution types.
本発明で使用されるヒドロキシプロピルメチルセルロールの粘性については、特に制限されないが、例えば、2重量%水溶液(20℃)において粘度1000mPa・s以上、好ましくは、1000~200000mPa・sであるものが挙げられる。ここで、当該粘度は、B型粘度計「TOKI SANGYO VISCOMETER TVB-10」(東機産業株式会社製)において、ローター:M3(回転速度:20rpm、時間:1min、単位:mPa・s)を使用して測定した値をいう。 The viscosity of the hydroxypropylmethyl cellulose used in the present invention is not particularly limited. mentioned. Here, the viscosity is measured using a rotor: M3 (rotation speed: 20 rpm, time: 1 min, unit: mPa s) in a B-type viscometer "TOKI SANGYO VISCOMETER TVB-10" (manufactured by Toki Sangyo Co., Ltd.). It is the value measured by
本発明の外用組成物において、ヒドロキシプロピルメチルセルロースは、市販品を使用することができる。ヒドロキシプロピルメチルセルロースの市販品としては、具体的には、信越化学工業株式会社製の「メトローズ90SH-100SR」、「メトローズ90SH-4000SR」、「メトローズ90SH-15000SR」、「メトローズ90SH-100000SR」、「メトローズ65SH-50」、「メトローズ65SH-400」、「メトローズ65SH-1500」、「メトローズ65SH-4000」、「メトローズ60SH-50」、「メトローズ60SH-4000」、「メトローズ60SH-10000」、「メトローズTC-5E」、「メトローズ90SH-100SR」、「メトローズ90SH-4000SR」、「メトローズ90SH-15000SR」、「メトローズ90SH-100000SR」、「メトローズTC-5M」、「メトローズTC-5R」、「メトローズTC-5S」、「メトローズSB-4」;ダウ・ケミカル日本株式会社製の「メトセルE4M」、「メトセルE4M」、「メトセル40-100」、「メトセル40-101」、「メトセル40-202」;松本油脂製薬株式会社製の「マーポローズ60MP-4000」等が挙げられる。 A commercially available hydroxypropylmethylcellulose can be used in the composition for external use of the present invention. Specific examples of commercial products of hydroxypropyl methylcellulose include Shin-Etsu Chemical Co., Ltd. "Metolose 90SH-100SR", "Metolose 90SH-4000SR", "Metolose 90SH-15000SR", "Metolose 90SH-100000SR", "Metolose 90SH-100000SR", METOLOSE 65SH-50", "METOLOSE 65SH-400", "METOLOSE 65SH-1500", "METOLOSE 65SH-4000", "METOLOSE 60SH-50", "METOLOSE 60SH-4000", "METOLOSE 60SH-10000", "METOLOSE TC-5E, METOLOSE 90SH-100SR, METOLOSE 90SH-4000SR, METOLOSE 90SH-15000SR, METOLOSE 90SH-100000SR, METOLOSE TC-5M, METOLOSE TC-5R, METOLOSE TC -5S", "Methocel SB-4"; "Methocel E4M", "Methocel E4M", "Methocel 40-100", "Methocel 40-101", "Methocel 40-202" manufactured by Dow Chemical Japan; "Marporose 60MP-4000" manufactured by Matsumoto Yushi Seiyaku Co., Ltd., and the like.
本発明の外用組成物において、ヒドロキシプロピルメチルセルロースは、1種のものを単独で使用してもよく、また2種以上のものを組み合わせて使用してもよい。 In the composition for external use of the present invention, hydroxypropylmethylcellulose may be used singly or in combination of two or more.
本発明の外用組成物において、(B)成分の含有量については、特に制限されず、外用組成物に付与すべき粘性や使用感等に応じて適宜設定すればよいが、例えば、0.1~5重量%が挙げられる。浮遊物や沈殿物の発生をより一層効果的に抑制するという観点から、(B)成分の含有量として、好ましくは0.1~3重量%、更に好ましくは0.3~2重量%、特に好ましくは0.3~1重量%が挙げられる。 In the composition for external use of the present invention, the content of the component (B) is not particularly limited, and may be appropriately set according to the viscosity to be imparted to the composition for external use and the feeling of use. ~5% by weight. From the viewpoint of more effectively suppressing the generation of suspended solids and sediments, the content of component (B) is preferably 0.1 to 3% by weight, more preferably 0.3 to 2% by weight, particularly 0.3 to 1% by weight is preferred.
本発明の外用組成物において、(A)成分に対する(B)成分の比率については、(A)成分及び(B)成分の各含有量に応じて定まるが、例えば、(A)成分100重量部当たり、(B)成分が50~3000重量部が挙げられる。(A)成分に対する(B)成分の比率として、浮遊物や沈殿物の発生をより一層効果的に抑制するという観点から、(A)成分100重量部当たり、(B)成分が、好ましくは100~2500重量部、更に好ましくは300~2000重量部が挙げられる。 In the composition for external use of the present invention, the ratio of component (B) to component (A) is determined according to the respective contents of component (A) and component (B). 50 to 3,000 parts by weight of the component (B) may be used per unit. The ratio of component (B) to component (A) is preferably 100 parts by weight of component (B) per 100 parts by weight of component (A) from the viewpoint of more effectively suppressing the generation of suspended solids and sediments. Up to 2500 parts by weight, more preferably 300 to 2000 parts by weight.
(C)ヘパリン類似物質
ヘパリン類似物質は、コンドロイチン多硫酸等の多硫酸化ムコ多糖であり、保湿作用、抗炎症作用、血行促進作用等を有することが知られている公知の薬剤である。本発明の外用組成物では、ヘパリン類似物質を含むことによって、ホスホコリン基含有重合体とヒドロキシプロピルメチルセルロースの共存下で生じる浮遊物や沈殿物の発生を抑制し、優れた外観性状を備えることが可能になっている。
(C) Heparin-like substances Heparin-like substances are polysulfated mucopolysaccharides such as chondroitin polysulfate, and are known drugs known to have moisturizing, anti-inflammatory, and blood circulation promoting effects. In the composition for external use of the present invention, by containing a heparin analogous substance, it is possible to suppress the generation of floating matter and sediment that occur in the coexistence of the phosphocholine group-containing polymer and hydroxypropylmethyl cellulose, and to have excellent appearance properties. It has become.
本発明で使用されるヘパリン類似物質の由来については、特に制限されないが、例えば、ムコ多糖類を多硫酸化することにより得られたもの、食用獣の組織(例えば、ウシやブタ等の気管軟骨を含む肺臓)から抽出したもの等が挙げられる。本発明の外用組成物では、ヘパリン類似物質として、日本薬局方外医薬品規格に収戴されているヘパリン類似物質が好適に使用される。 The origin of the heparin-like substance used in the present invention is not particularly limited, but examples include those obtained by polysulfating mucopolysaccharides, tissues of edible animals (e.g., tracheal cartilage of bovine, porcine, etc.). (including lungs), and the like. In the composition for external use of the present invention, as the heparinoid substance, a heparinoid substance included in the Japanese Pharmaceutical Standards outside the Pharmacopoeia is preferably used.
本発明の外用組成物における(C)成分の含有量については、特に制限されないが、例えば、0.01~5重量%が挙げられる。浮遊物や沈殿物の発生をより一層効果的に抑制するという観点から、(C)成分の含有量として、好ましくは0.05~3重量%、更に好ましくは0.1~1重量%、特に好ましくは0.3~1重量%が挙げられる。 The content of component (C) in the topical composition of the present invention is not particularly limited, but may be, for example, 0.01 to 5% by weight. From the viewpoint of more effectively suppressing the generation of suspended solids and sediments, the content of component (C) is preferably 0.05 to 3% by weight, more preferably 0.1 to 1% by weight, and particularly 0.3 to 1% by weight is preferred.
本発明の外用組成物において、(A)成分に対する(C)成分の比率については、(A)成分及び(B)成分の各含有量に応じて定まるが、例えば、(A)成分100重量部当たり、(C)成分が100~2000重量部が挙げられる。(A)成分に対する(C)成分の比率として、浮遊物や沈殿物の発生をより一層効果的に抑制するという観点から、(A)成分100重量部当たり、(C)成分が、好ましくは200~1500重量部、更に好ましくは300~1000重量部が挙げられる。 In the composition for external use of the present invention, the ratio of component (C) to component (A) is determined according to the respective contents of component (A) and component (B). 100 to 2,000 parts by weight of component (C) per unit. The ratio of component (C) to component (A) is preferably 200 parts by weight per 100 parts by weight of component (A) from the viewpoint of more effectively suppressing the generation of suspended solids and sediments. Up to 1500 parts by weight, more preferably 300 to 1000 parts by weight.
(D)多価アルコール
本発明の外用組成物は、前記(A)~(C)成分に加えて、必要に応じて、多価アルコール((D)と表記することもある)が含まれていてもよい。多価アルコールを含有することにより、優れた外観性状をより効果的に備えさせ得ることがあり、更に(A)成分による保湿作用を増強することもできる。
(D) Polyhydric alcohol The composition for external use of the present invention contains a polyhydric alcohol (sometimes referred to as (D)) in addition to the above components (A) to (C). may By containing a polyhydric alcohol, excellent appearance properties can be provided more effectively, and the moisturizing action of the component (A) can be enhanced.
多価アルコールとしては、薬学的又は香粧学的に許容されることを限度として特に制限されないが、例えば、1,3-ブチレングリコール、エチレングリコール、プロピレングリコール、イソプレングリコール、ジエチレングリコール、ジプロピレングリコール、ポリエチレングリコール、グリセリン等が挙げられる。これらの多価アルコールの中でも、好ましくは1,3-ブチレングリコール及びプロピレングリコールが挙げられる。 Polyhydric alcohols are not particularly limited as long as they are pharmaceutically or cosmetically acceptable. Examples include 1,3-butylene glycol, ethylene glycol, propylene glycol, isoprene glycol, diethylene glycol, dipropylene glycol, polyethylene glycol, glycerin, and the like. Among these polyhydric alcohols, 1,3-butylene glycol and propylene glycol are preferred.
これらの多価アルコールは、1種単独で使用してもよく、また2種以上を組み合わせて使用してもよい。 These polyhydric alcohols may be used singly or in combination of two or more.
本発明の外用組成物において、(D)成分を含有させる場合、その含有量については、使用する多価アルコールの種類等に応じて適宜設定すればよいが、例えば1重量%以上、好ましくは2~20重量%、更に好ましくは3~20重量%が挙げられる。 When the composition for external use of the present invention contains component (D), the content thereof may be appropriately set according to the type of polyhydric alcohol used. to 20% by weight, more preferably 3 to 20% by weight.
水
本発明の外用組成物は、水を含む水系組成物に調製される。本発明の外用組成物において、水の含有量については、製剤形態に応じて適宜設定すればよいが、例えば5~95重量%、好ましくは5~90重量%、更に好ましくは10~90重量%が挙げられる。
Water The topical composition of the present invention is prepared as an aqueous composition containing water. In the composition for external use of the present invention, the content of water may be appropriately set according to the form of the formulation, and is, for example, 5 to 95% by weight, preferably 5 to 90% by weight, more preferably 10 to 90% by weight. is mentioned.
その他の成分
本発明の外用組成物は、前述する成分の他に、必要に応じて、他の薬理成分を含有していてもよい。このような薬理成分としては、例えば、抗ヒスタミン剤(ジフェンヒドラミン、塩酸ジフェンヒドラミン等)、局所麻酔剤(プロカイン、テトラカイン、ブピパカイン、メピパカイン、クロロプロカイン、プロパラカイン、メプリルカイン又はこれらの塩、オルソカイン、オキセサゼイン、オキシポリエントキシデカン、ロートエキス、ペルカミンパーゼ、テシットデシチン等)、抗炎症剤(グリチルリチン酸二カリウム、グリチルレチン酸、インドメタシン、フェルビナク、ジクロフェナクナトリウム、ロキソプロフェンナトリウム等)、皮膚保護剤(コロジオン、ヒマシ油等)、血行促進成分(ノニル酸ワニリルアミド、ニコチン酸ベンジルエステル、カプサイシン、トウガラシエキス等)、清涼化剤(メントール、カンフル等)、ビタミン類(ビタミンA等)、ムコ多糖類(コンドロイチン硫酸ナトリウム、グルコサミン等)等が挙げられる。
Other Ingredients The composition for external use of the present invention may contain other pharmacological ingredients in addition to the ingredients described above, if necessary. Such pharmacological ingredients include, for example, antihistamines (diphenhydramine, diphenhydramine hydrochloride, etc.), local anesthetics (procaine, tetracaine, bupipacaine, mepipacaine, chloroprocaine, proparacaine, meprilcaine or salts thereof, orthocaine, oxethazein, oxypolyethoxylate). Decane, Rohto extract, percamimpase, tecit decithin, etc.), anti-inflammatory agents (dipotassium glycyrrhizinate, glycyrrhetinic acid, indomethacin, felbinac, diclofenac sodium, loxoprofen sodium, etc.), skin protective agents (collodion, castor oil, etc.), blood circulation promoting ingredients ( nonylic acid vanillylamide, benzyl nicotinate, capsaicin, red pepper extract, etc.), cooling agents (menthol, camphor, etc.), vitamins (vitamin A, etc.), mucopolysaccharides (sodium chondroitin sulfate, glucosamine, etc.).
また、本発明の外用組成物は、所望の製剤形態にするために、必要に応じて、前述する成分以外の基材や添加剤が含まれていてもよい。このような基剤や添加剤については、薬学的に許容されることを限度として特に制限されないが、例えば、油類(オリーブ油、サフラワー油、大豆油、つばき油、とうもろこし油、なたね油、ひまわり油、綿実油、落花生油、ラード、スクワラン、魚油等)、鉱物油(流動パラフィン、パラフィン、ゲル化炭化水素、ワセリン等)、ワックス類・ロウ類(ミツロウ、カルナウバロウ、キャンデリラロウ、セレシン、ライスワックス、マイクロクリスタリンワックス等)、エステル油(ミリスチン酸イソプロピル、アジピン酸イソプロピル、セバシン酸ジエチル、セバシン酸イソプロピル、パルミチン酸イソプロピル、パルミチン酸セチル、オレイン酸エチル等)、脂肪酸アルキルエステル、脂肪酸(ステアリン酸、オレイン酸、パルミチン酸、ベヘン酸、リノール酸、ラノリン等)、脂肪酸エステル(パルミチン酸セチル、パルミチン酸イソプロピル、リノール酸エチル等)、低級アルコール(エタノール、プロパノール、イソプロパノール、ブタノール、イソブタノール等)、高級アルコール(ステアリルアルコール、セタノール、ベヘニルアルコール、ミリスチルアルコール、オレイルアルコール、ヘキサデシルアルコール、ラノリンアルコール等)、コレステロール、トリ2-エチルヘキサン酸グリセリル、2-エチルヘキサン酸セチル、シリコーンオイル(ジメチルポリシロキサン、環状シリコーン等)等の油性基剤;POE(10~50モル)フィトステロールエーテル、POE(10~50モル)ジヒドロコレステロールエーテル、POE(10~50モル)2-オクチルドデシルエーテル、POE(10~50モル)デシルテトラデシルエーテル、POE(10~50モル)オレイルエーテル、POE(2~50モル)セチルエーテル、POE(5~50モル)ベヘニルエーテル、POE(5~30モル)ポリオキシプロピレン(5~30モル)2-デシルテトラデシルエーテル、POE(10~50モル)ポリオキシプロピレン(2~30モル)セチルエーテルなどのポリオキシエチレンアルキルエーテル、これらのリン酸・リン酸塩(POEセチルエーテルリン酸ナトリウムなど)、POE(20~60モル)ソルビタンモノオレート、POE(10~60モル)ソルビタンモノイソステアレート、POE(10~80モル)グリセリルモノイソステアレート、POE(10~30モル)グリセリルモノステアレート、POE(20~100モル)・ポリオキシプロピレン変性シリコーン、POE・アルキル変性シリコーン、モノラウリン酸ポリエチレングリコール、モノパルミチン酸ポリエチレングリコール、モノステアリン酸ポリエチレングリコール、ジラウリン酸ポリエチレングリコール、ジパルミチン酸ポリエチレングリコール、ジステアリン酸ポリエチレングリコール、ジオレイン酸ポリエチレングリコール、ジリシノレイン酸ポリエチレングリコール、ポリオキシエチレン硬化ヒマシ油(5~100)、ポリソルベート(20~85)、グリセリン脂肪酸エステル(モノステアリン酸グリセリン等)、水素添加大豆リン脂質、水素添加ラノリンアルコール等の界面活性剤;清涼化剤(メントール、カンフル、ボルネオール、ハッカ水、ハッカ油等)、防腐剤(メチルパラベン、プロピルパラベン、安息香酸、安息香酸ナトリウム、ソルビン酸等)、着香剤(シトラール、1,8-シオネール、シトロネラール、ファルネソール等)、着色剤(タール色素(褐色201号、青色201号、黄色4号、黄色403号等)、カカオ色素、クロロフィル、酸化アルミニウム等)、粘稠剤(カルボキシビニルポリマー、ポリビニルピロリドン、アルギン酸ナトリウム、エチルセルロース、カルボキシメチルセルロースナトリウム、キサンタンガム、カラギーナン等)、pH調整剤(リン酸、塩酸、クエン酸、クエン酸ナトリウム、コハク酸、酒石酸、水酸化ナトリウム、水酸化カリウム、トリエタノールアミン、トリイソプロパノールアミン等)、湿潤剤(dl-ピロリドンカルボン酸ナトリウム液、D-ソルビトール液、マクロゴール等)、安定化剤(ジブチルヒドロキシトルエン、ブチルヒドロキシアニソール、エデト酸ナトリウム、メタリン酸ナトリウム、L-アルギニン、L-アスパラギン酸、DL-アラニン、グリシン、エリソルビン酸ナトリウム、没食子酸プロピル、亜硫酸ナトリウム、二酸化硫黄、クロロゲン酸、カテキン、ローズマリー抽出物等)、酸化防止剤、紫外線吸収剤、キレート剤、粘着剤、緩衝剤、溶解補助剤、可溶化剤、保存剤等の添加剤が挙げられる。 In addition, the composition for external use of the present invention may, if necessary, contain base materials and additives other than the components described above in order to obtain a desired formulation form. Such bases and additives are not particularly limited as long as they are pharmaceutically acceptable. , cottonseed oil, peanut oil, lard, squalane, fish oil, etc.), mineral oil (liquid paraffin, paraffin, gelling hydrocarbon, petrolatum, etc.), waxes and waxes (beeswax, carnauba wax, candelilla wax, ceresin, rice wax, microcrystalline wax, etc.), ester oils (isopropyl myristate, isopropyl adipate, diethyl sebacate, isopropyl sebacate, isopropyl palmitate, cetyl palmitate, ethyl oleate, etc.), fatty acid alkyl esters, fatty acids (stearic acid, oleic acid) , palmitic acid, behenic acid, linoleic acid, lanolin, etc.), fatty acid esters (cetyl palmitate, isopropyl palmitate, ethyl linoleate, etc.), lower alcohols (ethanol, propanol, isopropanol, butanol, isobutanol, etc.), higher alcohols ( stearyl alcohol, cetanol, behenyl alcohol, myristyl alcohol, oleyl alcohol, hexadecyl alcohol, lanolin alcohol, etc.), cholesterol, glyceryl tri-2-ethylhexanoate, cetyl 2-ethylhexanoate, silicone oil (dimethylpolysiloxane, cyclic silicone, etc.) Oil base such as POE (10-50 mol) phytosterol ether, POE (10-50 mol) dihydrocholesterol ether, POE (10-50 mol) 2-octyldodecyl ether, POE (10-50 mol) decyltetradecyl Ether, POE (10-50 mol) oleyl ether, POE (2-50 mol) cetyl ether, POE (5-50 mol) behenyl ether, POE (5-30 mol) polyoxypropylene (5-30 mol) 2- Polyoxyethylene alkyl ethers such as decyltetradecyl ether, POE (10-50 mol) polyoxypropylene (2-30 mol) cetyl ether, their phosphoric acid/phosphate (POE cetyl ether sodium phosphate, etc.), POE (20-60 mol) sorbitan monooleate, POE (10-60 mol) sorbitan monoisostearate, POE (10-80 mol) glyceryl monoisostearate, POE (10-30 mol) glyceryl monostearate, POE ( 20 to 100 mol)-polyoxypropylene-modified silicone, POE-alkyl-modified silicone, polyethylene glycol monolaurate, polyethylene glycol monopalmitate, polyethylene glycol monostearate, polyethylene glycol dilaurate, polyethylene glycol dipalmitate, polyethylene glycol distearate , polyethylene glycol dioleate, polyethylene glycol diricinoleate, polyoxyethylene hydrogenated castor oil (5-100), polysorbate (20-85), glycerin fatty acid ester (glyceryl monostearate, etc.), hydrogenated soybean phospholipid, hydrogenation Surfactants such as lanolin alcohol; cooling agents (menthol, camphor, borneol, peppermint water, peppermint oil, etc.), preservatives (methylparaben, propylparaben, benzoic acid, sodium benzoate, sorbic acid, etc.), flavoring agents ( citral, 1,8-cioneal, citronellal, farnesol, etc.), coloring agents (tar pigments (brown No. 201, blue No. 201, yellow No. 4, yellow No. 403, etc.), cacao pigments, chlorophyll, aluminum oxide, etc.), viscous Agents (carboxyvinyl polymer, polyvinylpyrrolidone, sodium alginate, ethylcellulose, sodium carboxymethylcellulose, xanthan gum, carrageenan, etc.), pH adjusters (phosphoric acid, hydrochloric acid, citric acid, sodium citrate, succinic acid, tartaric acid, sodium hydroxide, water potassium oxide, triethanolamine, triisopropanolamine, etc.), wetting agents (sodium dl-pyrrolidonecarboxylate solution, D-sorbitol solution, macrogol, etc.), stabilizers (dibutylhydroxytoluene, butylhydroxyanisole, sodium edetate, sodium metaphosphate, L-arginine, L-aspartic acid, DL-alanine, glycine, sodium erythorbate, propyl gallate, sodium sulfite, sulfur dioxide, chlorogenic acid, catechin, rosemary extract, etc.), antioxidants, ultraviolet rays Additives such as absorbents, chelating agents, adhesives, buffers, solubilizers, solubilizers, and preservatives are included.
pH
本発明の外用組成物のpHについては、特に制限されず、肌に対する刺激性等を勘案して適宜設定すればよいが、例えば3~8、好ましくは3~7が挙げられる。
pH
The pH of the composition for external use of the present invention is not particularly limited, and may be appropriately set in consideration of skin irritation and the like.
製剤形態
本発明の予防又は治療剤は、経皮適用できる剤型である限り、その製剤形態については、特に制限されず、液状又は半固形状(ゲル状、ペースト状)のいずれであってもよい。
Formulation Form The form of the preventive or therapeutic agent of the present invention is not particularly limited as long as it is a dosage form that can be applied transdermally, and may be liquid or semi-solid (gel, paste). good.
本発明の外用組成物は、皮膚に適用されるものである限り、皮膚外用医薬品(医薬部外品を含む)、化粧料、皮膚洗浄料等のいずれの製剤形態であってもよい。本発明の外用組成物の製剤形態として、具体的には、ゲル剤、クリーム剤、ローション剤、乳液剤、液剤、貼付剤、エアゾール剤、軟膏剤、パック剤等の皮膚外用医薬品;ゲル、クリーム、乳液、化粧水、ローション、パック等の化粧料;ボディーシャンプー、ヘアシャンプー、リンス等の皮膚洗浄料等が挙げられる。これらの製剤形態の中でも、好ましくは皮膚外用医薬品、更に好ましくはゲル剤、ローション剤、及び液剤が挙げられる。 The composition for external use of the present invention may be in any formulation form, such as an external skin drug (including quasi-drugs), a cosmetic, or a skin cleanser, as long as it is applied to the skin. Specific formulations of the external composition of the present invention include gels, creams, lotions, milky lotions, liquids, patches, aerosols, ointments, skin external medicines such as packs; gels and creams. , cosmetics such as milky lotions, lotions, lotions and packs; skin cleansers such as body shampoos, hair shampoos and rinses. Among these formulation forms, skin preparations for external use are preferred, and gels, lotions, and liquids are more preferred.
本発明の外用組成物は、含有する(A)成分に基づいて保湿作用、角質層バリア機能等を発揮でき、更に含有する(C)成分に基づいて保湿作用、抗炎症作用、血行促進作用等を発揮できるので、保湿、肌荒れ改善、乾燥性皮膚疾患の予防又は治療、炎症性皮膚疾患の予防又は治療等の目的で好適に使用される。 The composition for external use of the present invention can exhibit moisturizing action, stratum corneum barrier function, etc. based on the component (A) it contains, and can exhibit moisturizing action, anti-inflammatory action, blood circulation promoting action, etc. based on the component (C) it further contains. Therefore, it is preferably used for purposes such as moisturizing, improving rough skin, preventing or treating dry skin diseases, and preventing or treating inflammatory skin diseases.
2.外用組成物の浮遊物及び/又は沈殿物の発生抑制方法
本発明は、更に、(A)ホスホコリン基含有重合体、及び(B)ヒドロキシプロピルメチルセルロースを含む外用組成物において、浮遊物及び/又は沈殿物の発生を抑制する方法であって、当該外用組成物に(C)ヘパリン類似物質を配合することを特徴とする、当該外用組成物の浮遊物及び/又は沈殿物の発生抑制方法を提供する。
2. A method for suppressing the generation of suspended solids and/or precipitates in a composition for external use The present invention further provides suspended solids and/or precipitates in a composition for external use containing (A) a phosphocholine group-containing polymer and (B) hydroxypropylmethylcellulose. A method for suppressing the generation of suspended solids and/or sediments in the composition for external use, which comprises blending (C) a heparin-like substance in the composition for external use. .
当該方法において、使用する(A)~(C)の種類や含有量、配合される他の成分の種類や含有量、外用組成物の製剤形態等については、前記「1.外用組成物」の場合と同様である。 In the method, the type and content of (A) to (C) used, the type and content of other ingredients to be blended, the form of formulation of the composition for external use, etc. are as described in "1. Composition for external use" above. It is the same as the case.
以下に実施例を示して本発明をより具体的に説明するが、本発明はこれらに限定されるものではない。
試験例
1.外用組成物の調製
表1に示す組成のゲル状外用組成物を調製した。具体的には、精製水に、所定量のヒドロキシプロピルメチルセルロース、ヘパリン類似物質、及びプロピレングリコールを加えて均一に分散、溶解させた後に、所定量の2-メタクリロイルオキシエチルホスホコリン・メタクリル酸ブチル共重合体を添加して混合することにより、ゲル状外用組成物を得た。
EXAMPLES The present invention will be described in more detail with reference to examples below, but the present invention is not limited to these.
Test example
1. Preparation of composition for external use A gel composition for external use having the composition shown in Table 1 was prepared. Specifically, a predetermined amount of hydroxypropylmethylcellulose, a heparin-like substance, and propylene glycol are added to purified water, uniformly dispersed and dissolved, and then a predetermined amount of 2-methacryloyloxyethylphosphocholine/butyl methacrylate is added. A gel composition for external use was obtained by adding and mixing the polymer.
2.外観性状の評価
得られた各外用組成物の製造直後の外観を目視にて確認し、外観性状を評価した。また、得られた各外用組成物を遮光条件下の20℃で1時間保存した後に、外観を目視にて確認し、外観性状を評価した。なお、外観性状は、以下の判定基準に従って評価した。
<外観性状の評価基準>
(沈殿の抑制)
◎:調製直後及び保存後に沈殿物は全く認められなかった。
○:調製直後に僅かに沈殿物が発生していたが、保存後には沈殿物は消失していた。
△:調製直後に僅かに沈殿物が発生しており、保存後でも沈殿物はそのまま残存していた。
×:調製直後に著しい沈殿物が発生しており、保存後でも沈殿物はそのまま残存していた。
(浮遊物の抑制)
◎:調製直後及び保存後に浮遊物が発生しておらず、白濁は全く認められなかった。
○:調製直後に僅かに浮遊物が発生して若干白濁が認められたが、保存後には浮遊物は消失して白濁は認められなかった。
△:調製直後に僅かに浮遊物が発生して若干白濁が認められ、保存後でも浮遊物はそのまま残存して白濁したままであった。
×:調製直後に著しい浮遊物が発生して白濁が顕著に認められ、保存後でも浮遊物はそのまま残存して顕著に白濁したままであった。
2. Evaluation of Appearance Properties The appearance of each external composition obtained immediately after production was visually confirmed to evaluate the appearance properties. In addition, after storing each of the obtained compositions for external use at 20° C. under light-shielding conditions for 1 hour, the external appearance was visually observed to evaluate the appearance properties. Appearance properties were evaluated according to the following criteria.
<Evaluation Criteria for Appearance Properties>
(Suppression of precipitation)
A: No precipitate was observed immediately after preparation and after storage.
◯: A slight precipitate was generated immediately after preparation, but the precipitate disappeared after storage.
Δ: A slight precipitate was generated immediately after preparation, and the precipitate remained as it was even after storage.
x: Significant precipitates were generated immediately after preparation, and the precipitates remained as they were even after storage.
(Suppression of floating matter)
⊚: Immediately after preparation and after storage, no suspended matter was observed, and cloudiness was not observed at all.
◯: Immediately after preparation, a slight amount of suspended matter was generated and a slight cloudiness was observed, but after storage, the suspended matter disappeared and no cloudiness was observed.
Δ: Immediately after preparation, a slight amount of suspended matter was generated and a slight cloudiness was observed, and even after storage, the suspended matter remained as it was and remained cloudy.
x: Immediately after preparation, significant cloudiness was observed due to the generation of significant floating matter.
3.結果
得られた結果を表1に示す。ヒドロキシプロピルメチルセルロースを単独で含む場合(参考例1)には浮遊物及び沈殿の発生は認められなかったが、2-メタクリロイルオキシエチルホスホコリン・メタクリル酸ブチル共重合体とヒドロキシプロピルメチルセルロースを併用した場合(比較例1及び2)では、著しい浮遊物及び沈殿の発生が認められた。これに対して、2-メタクリロイルオキシエチルホスホコリン・メタクリル酸ブチル共重合体とヒドロキシプロピルメチルセルロースと共に、ヘパリン類似物質を含む場合(実施例1~8)では、浮遊物及び沈殿の発生を十分に抑制できていた。
3. Results Table 1 shows the results obtained. When hydroxypropylmethylcellulose was contained alone (Reference Example 1), no floating matter or precipitate occurred, but when 2-methacryloyloxyethylphosphocholine-butyl methacrylate copolymer and hydroxypropylmethylcellulose were used in combination, In (Comparative Examples 1 and 2), significant floating matter and sedimentation were observed. On the other hand, when the heparin analogue is contained together with the 2-methacryloyloxyethylphosphocholine/butyl methacrylate copolymer and hydroxypropyl methylcellulose (Examples 1 to 8), the generation of suspended solids and precipitates is sufficiently suppressed. It was ready.
処方例
表2に示す外用組成物(液剤)、表3に示す外用組成物(ローション剤)、及び表4に示す外用組成物(ゲル剤)を調製した。得られた外用組成物について、前記試験例と同様の方法で外観性状の評価を行ったところ、いずれも浮遊物及び沈殿の発生を十分に抑制できていた。
Formulation Examples External compositions (liquid formulations) shown in Table 2, external compositions (lotions) shown in Table 3, and external compositions (gels) shown in Table 4 were prepared. When the appearance properties of the obtained compositions for external use were evaluated in the same manner as in the above test examples, the generation of suspended matter and sedimentation could be sufficiently suppressed in all cases.
Claims (5)
外用組成物に、(A)ホスホコリン基含有重合体、及び(B)ヒドロキシプロピルメチルセルロースと共に、(C)ヘパリン類似物質を配合する、
前記外用組成物の浮遊物及び/又は沈殿物の発生抑制方法。 A method for suppressing the generation of floating matter and/or sediment in an external composition containing a phosphocholine group-containing polymer and hydroxypropylmethylcellulose,
(A) a phosphocholine group-containing polymer and (B) hydroxypropylmethylcellulose, and (C) a heparin analogue are blended into the composition for external use;
A method for suppressing the generation of floating matter and/or sediments of the composition for external use.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023103320A JP2023120388A (en) | 2016-12-28 | 2023-06-23 | external composition |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016257088A JP2018108957A (en) | 2016-12-28 | 2016-12-28 | External composition |
JP2021130442A JP2021175753A (en) | 2016-12-28 | 2021-08-10 | External composition |
JP2023103320A JP2023120388A (en) | 2016-12-28 | 2023-06-23 | external composition |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021130442A Division JP2021175753A (en) | 2016-12-28 | 2021-08-10 | External composition |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2023120388A true JP2023120388A (en) | 2023-08-29 |
Family
ID=62844760
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016257088A Pending JP2018108957A (en) | 2016-12-28 | 2016-12-28 | External composition |
JP2021130442A Pending JP2021175753A (en) | 2016-12-28 | 2021-08-10 | External composition |
JP2023103320A Pending JP2023120388A (en) | 2016-12-28 | 2023-06-23 | external composition |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016257088A Pending JP2018108957A (en) | 2016-12-28 | 2016-12-28 | External composition |
JP2021130442A Pending JP2021175753A (en) | 2016-12-28 | 2021-08-10 | External composition |
Country Status (1)
Country | Link |
---|---|
JP (3) | JP2018108957A (en) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0952848A (en) * | 1995-08-07 | 1997-02-25 | Pola Chem Ind Inc | Skin preparation for external use |
JP2005060234A (en) * | 2003-08-08 | 2005-03-10 | Rohto Pharmaceut Co Ltd | External preparation for skin |
JP2010070523A (en) * | 2008-09-22 | 2010-04-02 | Kowa Co | Oil-in-water type emulsion composition |
JP5827052B2 (en) * | 2010-07-16 | 2015-12-02 | ロート製薬株式会社 | Composition for external use |
-
2016
- 2016-12-28 JP JP2016257088A patent/JP2018108957A/en active Pending
-
2021
- 2021-08-10 JP JP2021130442A patent/JP2021175753A/en active Pending
-
2023
- 2023-06-23 JP JP2023103320A patent/JP2023120388A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2018108957A (en) | 2018-07-12 |
JP2021175753A (en) | 2021-11-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5897164B2 (en) | Composition for external use | |
JP6666068B2 (en) | External composition | |
JP4786630B2 (en) | Topical skin preparation | |
JP2005060234A (en) | External preparation for skin | |
JP6765299B2 (en) | Aqueous formulation | |
JP4972895B2 (en) | Urea formulation for external use | |
US11872304B2 (en) | Topical composition | |
JP6628488B2 (en) | External gel composition | |
JP7313111B2 (en) | Sebum secretion stimulator and composition for external use | |
JP2016179958A (en) | Skin pigmentation inhibitor | |
JP7282476B2 (en) | external composition | |
EP2306999A2 (en) | Compositions for treating rosacea | |
JP2023120388A (en) | external composition | |
JP2000038352A (en) | Composition for external use | |
JP6807636B2 (en) | Topical composition | |
JP2005060233A (en) | External preparation for skin | |
JP6851139B2 (en) | Topical composition | |
JP2021098655A (en) | Skin external composition | |
JP6735587B2 (en) | External composition | |
JP7153429B2 (en) | Active oxygen scavenging agent | |
JP7214331B2 (en) | Pharmaceutical composition | |
JP2023001391A (en) | Pharmaceutical composition | |
JP2022169466A (en) | Heparinoid-containing gel composition and method for suppressing decrease in viscosity thereof | |
JP2019006697A (en) | Active oxygen scavenger | |
JP2021001227A (en) | External composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230721 |